CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 10), or a salt thereof; or

a modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 11), or a salt thereof; or

a modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 12), or a salt thereof; or

a modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 9), or a salt thereof; or

a modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 13), or a salt thereof; or

a modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 14), or a salt thereof.

2. The modified oligonucleotide of claim 1, which is the sodium salt or the potassium salt.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO 10); or



(SEQ ID NO 11); or



(SEQ ID NO 12); or



(SEQ ID NO 9); or



(SEQ ID NO 13); or



(SEQ ID NO 14).

4. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:

$T_{es}{}^{m}C_{eo}G_{eo}{}^{m}C_{eo}{}^{m}C_{es}T_{ds}A_{ds}A_{ds}T_{ds}T_{ds}T_{ds}T_{ds}T_{ds}{}^{m}C_{ds}T_{ds}{}^{m}C_{eo}T_{eo}{}^{m}C_{es}A_{es}{}^{m}C_{e}$ (SEQ ID NO 10);

$^{m}C_{es}T_{eo}T_{eo}T_{eo}T_{eo}T_{eo}{}^{m}C_{ds}T_{ds}G_{ds}{}^{m}C_{ds}T_{ds}{}^{m}C_{ds}T_{ds}T_{ds}A_{ds}T_{ds}A_{eo}{}^{m}C_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO 11);

$^{m}C_{es}T_{eo}G_{eo}T_{eo}T_{eo}T_{eo}T_{ds}A_{ds}{}^{m}C_{ds}A_{ds}T_{ds}T_{ds}T_{ds}T_{ds}T_{ds}T_{ds}T_{eo}T_{es}{}^{m}C_{es}{}^{m}C_{e}$ (SEQ ID NO 12);

$T_{es}T_{eo}T_{eo}A_{eo}T_{es}{}^{m}C_{ds}{}^{m}C_{ds}A_{ds}A_{ds}T_{ds}T_{ds}A_{ds}T_{ds}{}^{m}C_{ds}{}^{m}C_{ds}A_{eo}T_{eo}{}^{m}C_{es}{}^{m}C_{es}{}^{m}C_{e}$ (SEQ ID NO 9);

$T_{es}T_{eo}T_{eo}{}^{m}C_{eo}A_{eo}T_{eo}A_{ds}T_{ds}T_{ds}T_{ds}G_{ds}T_{ds}T_{ds}A_{ds}{}^{m}C_{ds}T_{ds}T_{eo}{}^{m}C_{es}{}^{m}C_{es}T_{e}$ (SEQ ID NO 13); or

$T_{es}T_{eo}{}^{m}C_{eo}G_{eo}{}^{m}C_{eo}{}^{m}C_{eo}T_{ds}A_{ds}A_{ds}T_{ds}T_{ds}T_{ds}T_{ds}T_{ds}{}^{m}C_{ds}T_{ds}{}^{m}C_{eo}T_{es}{}^{m}C_{es}A_{e}$ (SEQ ID NO 14),

wherein:

A = an adenine nucleobase,

^{m}C = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

d = a 2'-β-D-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

5. A population of modified oligonucleotides of any of claims 1-3 or a population of oligomeric compounds of claim 4, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

6. A pharmaceutical composition comprising a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, or a population of modified oligonucleotides or population of oligomeric compounds of claim 5, and a pharmaceutically acceptable diluent.

7. The pharmaceutical composition of claim 6, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid, phosphate-buffered saline or sterile water.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide, the oligomeric compound, or the population of modified oligonucleotides or population of oligomeric compounds, and artificial cerebrospinal fluid, phosphate-buffered saline or sterile water

9. A modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, a population of modified oligonucleotides or population of oligomeric compounds of claim 5, or a pharmaceutical composition of any of claims 6-8 for use as a medicament.

10. Use of a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, a population of modified oligonucleotides or population of oligomeric compounds of claim 5, or a pharmaceutical composition of any of claims 6-8; in the manufacture of a medicament for the treatment of a disease associated with type I interferon signaling, wherein a therapeutically effective amount of the modified oligonucleotide, the oligomeric compound, the population of modified oligonucleotides or population of oligomeric compounds is to be administered to a subject having the disease associated with type I interferon signaling.

11. The use of claim 10, wherein the disease associated with type I interferon signaling is Aicardi-Goutières Syndrome, stroke, Neuropsychiatric Systemic Lupus Erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, or ataxia telangiectasia.

12. The use of claim 10 or claim 11, wherein the disease is associated with an elevated level of interferon-alpha.

13. The use of any of claims 10-12, wherein administration of the modified oligonucleotide, the oligomeric compound, the population of modified oligonucleotides or population of oligomeric compounds, or the pharmaceutical composition reduces seizures, dystonia, spasticity, white matter abnormalities, T cell infiltration, B cell infiltration, striatal necrosis, brain atrophy, basal ganglia calcification, or microencephaly in

the subject; improves feeding, motor development, language development, or social skill development in the subject; or reduces interferon alpha or lymphocytosis in the cerebrospinal fluid of the subject.

14. The use of claim 13, wherein the subject is human.